Universal Testing Necessary to Detect Oropharyngeal Gonorrhea Infections
Researchers assessed the optimal testing strategy for oropharyngeal N gonorrhoeae using surveillance data from all sexually transmitted infection clinics.
Researchers assessed the optimal testing strategy for oropharyngeal N gonorrhoeae using surveillance data from all sexually transmitted infection clinics.
A single 500 mg intramuscular dose of ceftriaxone is recommended for treatment of uncomplicated urogenital, anorectal, and pharyngeal gonorrhea.
Isolates were clustered based on patient sexual behavior and race/ethnicity to assess antibiotic resistance as a major driver of gonorrhea transmission in NYC.
Research results highlighted the need for continued supplemental NAATs for oropharyngeal samples being tested for Nisseria gonorrhoeae.
For patients with gonorrhea, detection of the wild-type serine 91 genotype of the gyrA gene of Neisseria gonorrhoeae is predictive of a successful treatment outcome with ciprofloxacin.
The FDA has granted Breakthrough Device designation to ResistancePlus GC,, a test that detects ciprofloxacin susceptibility.
Meningococcal vaccine antigens may generate an immune response that recognizes gonococcal proteins.
Zoliflodacin was effective in treating gonococcal urogenital and rectal infections, but less effective in the treatment of pharyngeal gonorrhea.
Gepotidacin, a novel triazaacenaphthelene bacterial type II topoisomerase inhibitor shows potential in treating resistant Neisseria gonorrhoeae.
Nearly 2.3 million cases of chlamydia, gonorrhea, and syphilis were diagnosed in the United States in 2017.